Monopar Therapeutics (MNPR) Retained Earnings (2016 - 2025)

Monopar Therapeutics has disclosed Retained Earnings across 9 years of filings, most recently posting -$89.5 million for Q4 2025.

• Retained Earnings for Q4 2025 came in at -$89.5 million, down 248766.37% year-over-year; the trailing twelve-month figure through Dec 2025 was -$89.5 million (down 248766.37% YoY), and the FY2025 annual result was -$89.5 million, down 248766.37% from the prior year.
• Retained Earnings came in at -$89.5 million for Q4 2025 at Monopar Therapeutics, down from $11698.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $42985.0 in Q3 2022 to a low of -$89.5 million in Q4 2025.
• The 5-year median for Retained Earnings is -$42.5 million (2021), against an average of -$37.8 million.
• Across the five-year window, Retained Earnings slumped 857815.38% in 2022 and soared 206.43% in 2025, its largest moves.
• Monopar Therapeutics' Retained Earnings stood at -$41.3 million in 2021, then slipped by 25.47% to -$51.8 million in 2022, then declined by 16.22% to -$60.2 million in 2023, then soared by 100.06% to $35992.0 in 2024, then slumped by 248766.37% to -$89.5 million in 2025.
• The last three Retained Earnings figures came in at -$89.5 million (Q4 2025), $11698.0 (Q3 2025), and -$80.9 million (Q2 2025), per Business Quant data.